|
AU2013263817A1
|
|
High affinity anti-human IgE antibodies
|
|
AU2012261739A1
|
|
Identification of novel IgE epitopes
|
|
US2011200604A1
|
|
IDENTIFICATION OF NOVEL IgE EPITOPES
|
|
AU2008201993A1
|
|
Synergistic compositions for the prevention and treatment of acquired immunodeficiency syndrome
|
|
WO2008140455A1
|
|
Treatment of radiation and chemo-therapy induced fibrosis using novel anti-il 13 monoclonal antibodies
|
|
WO2007094983A2
|
|
Methods and compositions for the inhibition of hiv infection of t cells
|
|
WO2007081777A2
|
|
METHODS FOR ACCURATELY MEASURING FREE IgE IN THE PRESENCE OF AN ANTI-IgE THERAPEUTIC
|
|
CA2597996A1
|
|
Methods for determining the bivalency of protein and antibody therapeutics
|
|
AU2006200377A1
|
|
Tissue factor antagonists and methods of use thereof
|
|
US2007299005A1
|
|
Family of genes encoding apoptosis-related peptides, peptides encoded thereby and methods of use thereof
|
|
US2009017016A1
|
|
Treatment and prevention of hypersensitivity and/or anaphylaxis with anti-ige antibodies in patients receiving replacement therapy
|
|
EP1786826A2
|
|
Thymic stromal lymphopoietin promoter and uses therefor
|
|
CN101035807A
|
|
Diagnosis and treatment of SIGLEC-6 associated diseases
|
|
AU2005255423A1
|
|
Diagnosis and treatment of SIGLEC-6 associated diseases
|
|
US2005232920A1
|
|
Inhibition of complement activation
|
|
WO2005071410A1
|
|
Detecting and quantifying host cell proteins in recombinant protein products
|
|
WO2005062967A2
|
|
Novel anti-il 13 antibodies and uses thereof
|
|
KR20060130557A
|
|
Human immunodeficiency virus entry inhibitor assay
|
|
CN1926149A
|
|
Identification of novel IgE epitopes
|
|
KR20140021058A
|
|
Identification of novel ige epitopes
|
